Remoxy Time Release Oxycodone Phase III Trial Planned For Year-End
Pain Therapeutics says drug is bioequivalent to Oxycontin and will consider filing under ANDA pathway. Labeling may contain fewer drug abuse warnings compared to Oxycontin.
Pain Therapeutics says drug is bioequivalent to Oxycontin and will consider filing under ANDA pathway. Labeling may contain fewer drug abuse warnings compared to Oxycontin.